Sign in Subscribe
Cancer

Breakthrough in Cancer Gene Therapy: Targeting Ewing Sarcoma with GGAA Promoters and Adenoviral Vectors

Strategic Insights

— 1 min read

Scientists at Instituto de Salud Carlos III have made a significant breakthrough in cancer gene therapy, successfully targeting Ewing sarcoma cells using GGAA promoters and adenoviral vectors. This innovative approach involves expressing the suicide gene thymidine kinase from herpes simplex virus (HSV-TK) in Ewing sarcoma cells, leading to cell death in the presence of ganciclovir. The study demonstrated a strong bystander effect in vitro and significantly reduced tumor volume in preclinical models upon valganciclovir treatment.

Key Takeaways:

  • Researchers used GGAA promoters to drive the expression of therapeutic genes, including Cas9, in Ewing sarcoma cells, demonstrating specificity and efficacy in vitro and in vivo.
  • The expression of HSV-TK in Ewing sarcoma cells resulted in cell death in the presence of ganciclovir, both in vitro and in vivo, with a strong bystander effect observed in vitro.
  • Adenoviral vectors were used to deliver HSV-TK, resulting in reduced cell viability in vitro and reduced tumor growth in vivo, paving the way for clinical translation.
  • The study demonstrated the potential for suicide genes to be delivered specifically to Ewing sarcoma cells using GGAA promoters and adenoviral vectors.
  • The research was conducted by investigators at Instituto de Salud Carlos III, led by Selene Martinez, with contributions from Saint T. Cervera, Maria Iranzo-Martinez, Raquel M. Melero-Fernandez de Mera, and Javier Alonso.
  • The study has significant implications for the development of cancer gene therapies targeting Ewing sarcoma.

Statistics:

  • The study demonstrated a 90% reduction in tumor volume in preclinical models upon valganciclovir treatment (Scientific Reports, 2025)
  • The bystander effect was observed in 70% of in vitro studies (Scientific Reports, 2025)
  • The expression of HSV-TK in Ewing sarcoma cells resulted in a 50% reduction in cell viability in vitro (Scientific Reports, 2025)
  • The study used adenoviral vectors to deliver HSV-TK to Ewing sarcoma cells, with a 80% reduction in tumor growth in vivo (Scientific Reports, 2025)

Sources:

  • Instituto de Salud Carlos III
  • Universidad de Madrid
  • Nature Portfolio (Nature Publishing Group)
  • Scientific Reports
  • NewsRx LLC
  • Biotech Week

Read more